Iterum Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Iterum Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-23.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-23.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Jul 05

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04

Iterum Therapeutics shares slide 13% on raising $10M

Feb 03

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Dec 03

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Nov 30

Iterum Therapeutics EPS beats by $0.45

Nov 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ITRM şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ITRM şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Iterum Therapeutics Piyasaya Karşı Temettü Getirisi

ITRM temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ITRM)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (ITRM) (3 yıla kadar)	n/a

Önemli Temettü: ITRM şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ITRM şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ITRM şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ITRM herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Iterum Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)

Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024

Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024

Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity Requirement

New major risk - Shareholder dilution

Forecast to breakeven in 2026

Iterum Therapeutics plc to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Shareholder dilution

Iterum Therapeutics plc Broadens Patent Estate for Oral Sulopenem

New major risk - Financial position

Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics plc to Report Q1, 2024 Results on May 13, 2024

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Iterum Therapeutics plc, Annual General Meeting, Jun 19, 2024

Insufficient new directors

Iterum Therapeutics plc to Report Q4, 2023 Results on Mar 28, 2024

Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections

New major risk - Financial position

Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023

New major risk - Revenue and earnings growth

Iterum Therapeutics plc to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Iterum Therapeutics plc to Report Q2, 2023 Results on Aug 11, 2023

Iterum Therapeutics plc, Annual General Meeting, May 03, 2023

Iterum Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022

Iterum Therapeutics plc to Report Q4, 2021 Results on Mar 28, 2022

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plc

Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain Officers

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecid

Independent Director Mohammed Shahzad Malik has left the company

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Consensus forecasts updated

Iterum Therapeutics plc Provides Update on NDA Review

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Price target increased to US$2.00

Consensus revenue estimates increase to US$2.86m

Independent Director has left the company

Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Iterum Therapeutics plc to Report Q4, 2020 Results on Mar 12, 2021

New 90-day high: US$2.27

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Iterum Therapeutics shares slide 13% on raising $10M

Iterum Therapeutics plc Announces Collaboration with Eversana to Support Oral Sulopenem Launch

President recently sold US$148k worth of stock

Iterum Therapeutics plc Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

New 90-day high: US$1.23

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Earnings beat expectations

Iterum Therapeutics EPS beats by $0.45

Iterum Therapeutics plc has completed a Follow-on Equity Offering in the amount of $17.385884 million.

New 90-day low: US$0.53

Iterum Therapeutics plc Plans to Proceed with an NDA Submission for sulopenem etzadroxil/probenecid

New 90-day low - US$0.68

Iterum Therapeutics plc has completed a Composite Units Offering in the amount of $6.374 million.

New 90-day low - US$0.98